As previously reported, Evercore ISI analyst Vijay Kumar upgraded Boston Scientific to Outperform and raised his price target to $42.50 from $39. The analyst says that the "healthy skepticism" toward his outlook for the company's back half revenue growth potential "creates an opportunity", stating that the worst case scenario of Boston Scientific's paclitaxel coated devices being pulled from market is off the table. Instead, Kumar believes that the company can generate 7%-8% revenue growth into FY20 - the highest rate among its peers - while offering a discount valuation.

Stifel raised the firm's price target on Boston Scientific to $83 from $70 and keeps a Buy rating on the shares. The firm said the company delivered "solid" Q1 outperformance, underpinned by "important" new product launches. Looking ahead to 2024 and beyond, Stifel believes Boston Scientific could continue outperforming their Loan Repayment Program and the firm's projections.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here